Commercially Available Cannabis Products for Immune Support
Launched by CENTER FOR INTERVENTIONAL PAIN AND SPINE · Jul 6, 2023
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how commercially available hemp and cannabis products might help support the immune system in people with illnesses like influenza, COVID-19, or the common cold. The study is currently recruiting participants aged 18 and older who are part of the Pennsylvania medical marijuana program. To join, individuals must be experiencing symptoms such as fever, cough, fatigue, or sore throat, and they need to agree to use a specific hemp or cannabis product throughout the study.
Participants will fill out questionnaires and stay in touch through a smartphone or email, helping researchers understand the effects of these products on their symptoms. However, some people can't join, like those who are pregnant, have certain allergies, or are seriously ill. It's a great opportunity for those who qualify to contribute to understanding how these products might aid in immune support during common illnesses.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. 18 years of age or older
- • 2. Able to read and write in English
- • 3. Active participants in the Pennsylvania medical marijuana program (for cannabis product users)
- 4. Currently experiencing one or more of the following symptoms due to an acute illness:
- • 1. Fever or chills
- • 2. Cough
- • 3. Fatigue
- • 4. Muscle or body aches
- • 5. Headache
- • 6. Sore throat
- • 7. Congestion or runny nose
- • 8. Nausea or Vomiting
- • 9. Diarrhea
- • 5. Agrees to consume their chosen hemp or cannabis product (for the cannabis arm) and to not use a different hemp or cannabis product through the duration of the study
- • 6. Agrees to continue to abstain from using hemp or cannabis (for the non-cannabis/hemp using arm)
- • 7. Must have smart phone or email and access to the internet
- • 8. Be able to comply with study requirements including baseline, completion of electronic questionnaires, and study timeline parameters.
- Exclusion Criteria:
- • 1. Women who are pregnant, breastfeeding, or planning to become pregnant.
- • 2. Known allergy to any compounds in hemp or cannabis.
- • 3. Endorses suicidal intent
- • 4. Immunocompromised individuals
- • 5. Unwilling or unable to comply with study procedures
- • 6. Terminal Illness with life expectancy less than 1 year
About Center For Interventional Pain And Spine
The Center for Interventional Pain and Spine is a leading clinical research organization dedicated to advancing the field of pain management through innovative interventional techniques. With a focus on improving patient outcomes, the center conducts rigorous clinical trials that explore cutting-edge therapies and interventions for various pain conditions. Committed to ethical standards and patient safety, the organization collaborates with healthcare professionals and researchers to contribute to the evolving landscape of pain management, ensuring that the latest evidence-based practices are accessible to patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bryn Mawr, Pennsylvania, United States
Patients applied
Trial Officials
Philip Kim, MD
Principal Investigator
Center For Interventional Pain and Spine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported